The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Randomized Trial Comparing Iridium Implant Plus External-Beam Radiation Therapy With External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate
Abstract
Purpose: To determine if iridium implant (IM) and external-beam radiation therapy (EBRT) is better than standard EBRT in locally advanced prostate cancer. Methods: Patients with T2 and T3 prostate cancer with no evidence of metastatic disease were randomly assigned to EBRT of 66 Gy in 33 fractions during 6.5 weeks or to IM of 35 Gy delivered to the prostate during 48 hours plus EBRT of 40 Gy in 20 fractions during 4 weeks. The primary outcome consisted of biochemical or clinical failure (BCF). BCF was defined by biochemical failure, clinical failure, or death as a result of prostate cancer. Secondary outcomes included 2-year postradiation biopsy positivity, toxicity, and survival. Results: Between 1992 and 1997, 51 patients were randomly assigned to receive IM plus EBRT, and 53 patients were randomly assigned to receive EBRT alone. The median follow-up was 8.2 years. In the IM plus EBRT arm, 17 patients (29%) experienced BCF compared with 33 patients (61%) in the EBRT arm (hazard ratio, 0.42; P = .0024). Eighty-seven patients (84%) had a postradiation biopsy; 10 (24%) of 42 in the IM plus EBRT arm had biopsy positivity compared with 23 (51%) of 45 in the EBRT arm (odds ratio, 0.30; P = .015). Overall survival was 94% in the IM plus EBRT arm versus 92% in the EBRT arm. Conclusion: The combination of IM plus EBRT was superior to EBRT alone for BCF and postradiation biopsy. This trial provides evidence that higher doses of radiation delivered in a shorter duration result in better local as well as biochemical control in locally advanced prostrate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Partin, A. W. (1997) · JAMA · doi:10.1001/jama.277.18.1445 · Cited by 1,794
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686
Consensus statement: Guidelines for PSA following radiation therapy1
AMERICANSOCIETYFORTHERAPEUTICR (1997) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00002-3 · Cited by 1,151
ZELEFSKY, M. J., FUKS, Z., HUNT, M., LEE, H. J., LOMBARDI, D., LING, C. C., REUTER, V. E., VENKATRAMAN, E. S., & LEIBEL, S. A. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65855-7 · Cited by 697
Hanks, G. E., Pajak, T. F., Porter, A., Grignon, D., Brereton, H., Venkatesan, V., Horwitz, E. M., Lawton, C., Rosenthal, S. A., Sandler, H. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.023 · Cited by 689
Pollack, A., Zagars, G. K., Smith, L. G., Lee, J. J., von Eschenbach, A. C., Antolak, J. A., Starkschall, G., & Rosen, I. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3904 · Cited by 521
Shipley, W. U., Verhey, L. J., Munzenrider, J. E., Suit, H. D., Urie, M. M., McManus, P. L., Young, R. H., Shipley, J. W., Zietman, A. L., Biggs, P. J., et al. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00063-5 · Cited by 407
Lawton, C. A., Winter, K., Murray, K., Machtay, M., Mesic, J. B., Hanks, G. E., Coughlin, C. T., & Pilepich, M. V. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01516-9 · Cited by 374
Long‐term effects of androgen deprivation therapy in prostate cancer patients
Basaria, S., Lieb, J., Tang, A. M., DeWeese, T., Carducci, M., Eisenberger, M., & Dobs, A. S. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01551.x · Cited by 359
Ragde, H., Elgamal, A.-A. A., Snow, P. B., Brandt, J., Bartolucci, A. A., Nadir, B. S., & Korb, L. J. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980901)83:5<989::aid-cncr26>3.0.co;2-q · Cited by 353
Dose response in prostate cancer with 8–12 years’ follow-up
Hanks, G. E., Hanlon, A. L., Epstein, B. E., et al. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02954-1 · Cited by 194
Pollack, A. S., Smith, L., & von Eschenbach, A. C. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00620-9 · Cited by 144
Hanks, G. E., Hanlon, A., Pinover, W. H., Horwitz, E. M., & Schultheiss, T. E. (1999) · PubMed · Cited by 110
3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review
Fiveash, J. B., Hanks, G. E., Roach, M., Wang, S., Vigneault, É., McLaughlin, P. W., & Sandler, H. M. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00441-7 · Cited by 99
High-Dose-Rate Brachytherapy in the Treatment of Carcinoma of the Prostate
Syed, A. M. N., Puthawala, A. A., Sharma, A. K., Gamie, S. H., Londrc, A., Cherlow, J. M., Damore, S. J., Nazmy, N., Sheikh, K. M. A., & Ko, S. J. (2001) · Cancer Control · doi:10.1177/107327480100800606 · Cited by 40
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Wilt, T. J., MacDonald, R., Rutks, I., Shamliyan, T. A., Taylor, B. C., & Kane, R. L. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-6-200803180-00209 · Cited by 597
Miralbell, R., Roberts, S. A., Zubizarreta, E., & Hendry, J. H. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.10.075 · Cited by 523
High-risk prostate cancer—classification and therapy
Chang, A. J., Autio, K. A., Roach, M., & Scher, H. I. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.68 · Cited by 500
Viani, G. A., Stefano, E. J., & Afonso, S. L. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.091 · Cited by 469
Metadata
- Authors
- Sathya, J. R., Davis, I. R., Julian, J. A., Guo, Q., Daya, D., Dayes, I. S., Lukka, H. R., & Levine, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-02-20
- Volume
- 23
- Issue
- 6
- Pages
- 1192-1199
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163954169
- Cited by
- 396
- References
- 15
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.